CancerIQ
Amount undisclosed
Funding date
Valuation / Funding
No funding history available
Funding data has not been imported for this company yet
Current Valuation Metrics
CancerIQ is currently valued at N/A as of August 21, 2024. The company has raised a total of $30.8M in funding.
Investment Perspective
CancerIQ's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.
What is CancerIQ Worth in 2025?
As of 2025, CancerIQ is valued at N/A, based on the company's Later Stage VC funding round in August 21, 2024. This valuation positions CancerIQ as one of the leading private companies in the sector.
CancerIQ Valuation History
CancerIQ's funding history demonstrates steady growth and investor confidence.
How CancerIQ Valuation is Determined
Private company valuations like CancerIQ's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:
- Revenue growth and financial performance
- Market opportunity and total addressable market (TAM)
- Competitive positioning and market share
- Management team strength and execution capability
- Technology and intellectual property
- Industry trends and investor sentiment
CancerIQ Valuation FAQs
Is CancerIQ profitable?
CancerIQ has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.
How does CancerIQ's valuation compare to competitors?
CancerIQ is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.
When will CancerIQ IPO?
CancerIQ has not announced plans for an initial public offering. Until an IPO, investors can access CancerIQ shares through secondary market platforms.